Abstract：
OBJECTIVE: To evaluate the short-term effect of intravitreal bevacizumab (avastin) injection on visual outcomes of patients with diabetic macular oedema.
METHODS: A retrospective cross-sectional study was conducted to evaluate 39 eyes of thirty-nine patients (mean age ± SD: 61.4 ± 15.0 years) that received intravitreal bevacizumab injection (1.25 mg in 0.05 ml) as treatment for diabetic macular oedema between January 2014 and July 2019 in Ghana. Data on visual acuity and central macular thickness before treatment and 6 weeks post-treatment were collected and analysed using paired t-test. Ordinary least squares linear regression analysis was also conducted to determine the relationship between improvement in visual acuity and central macular thickness after treatment and other predictor variables.
RESULTS: The mean ± SD visual acuity (LogMAR-equivalent of Snellen) of patients with diabetic macular oedema significantly improved from 0.84 ± 0.58 LogMAR before treatment to 0.69 ± 0.58 LogMAR at 6 weeks post-treatment (mean difference: 0.15 ± 0.32 LogMAR; 95% CI: 0.04 to 0.25; p = 0.01). Mean macular thickness ± SD on the other hand, reduced significantly (p < 0.001) from 316.54 ± 75.35 μm before treatment to 275.54 ± 57.43 μm after treatment. While age and worse pre-treatment visual acuity predicted improvement in visual acuity after treatment, a higher central macular thickness before treatment predicted an improvement in central macular thickness after intravitreal bevacizumab injection.
CONCLUSIONS: Treatment with intravitreal bevacizumab injection produces short-term improvement in vision and reduction in central macular thickness in African patients with diabetic macular oedema.
METHODS: A retrospective cross-sectional study was conducted to evaluate 39 eyes of thirty-nine patients (mean age ± SD: 61.4 ± 15.0 years) that received intravitreal bevacizumab injection (1.25 mg in 0.05 ml) as treatment for diabetic macular oedema between January 2014 and July 2019 in Ghana. Data on visual acuity and central macular thickness before treatment and 6 weeks post-treatment were collected and analysed using paired t-test. Ordinary least squares linear regression analysis was also conducted to determine the relationship between improvement in visual acuity and central macular thickness after treatment and other predictor variables.
RESULTS: The mean ± SD visual acuity (LogMAR-equivalent of Snellen) of patients with diabetic macular oedema significantly improved from 0.84 ± 0.58 LogMAR before treatment to 0.69 ± 0.58 LogMAR at 6 weeks post-treatment (mean difference: 0.15 ± 0.32 LogMAR; 95% CI: 0.04 to 0.25; p = 0.01). Mean macular thickness ± SD on the other hand, reduced significantly (p < 0.001) from 316.54 ± 75.35 μm before treatment to 275.54 ± 57.43 μm after treatment. While age and worse pre-treatment visual acuity predicted improvement in visual acuity after treatment, a higher central macular thickness before treatment predicted an improvement in central macular thickness after intravitreal bevacizumab injection.
CONCLUSIONS: Treatment with intravitreal bevacizumab injection produces short-term improvement in vision and reduction in central macular thickness in African patients with diabetic macular oedema.
摘要：
目的：评估玻璃体内注射贝伐单抗（avastin）对糖尿病性黄斑水肿患者视力预后的短期影响。
方法：进行了一项回顾性横断面研究，以评估2014年1月至2019年7月在加纳接受玻璃体内贝伐单抗注射（1.25mg/0.05ml）治疗糖尿病性黄斑水肿的39例患者（平均年龄±SD：61.4±15.0岁）的39只眼。收集治疗前和治疗后6周的视力和黄斑中心厚度的数据，并使用配对t检验进行分析。还进行了普通最小二乘线性回归分析，以确定视力改善与治疗后黄斑中心厚度和其他预测变量之间的关系。
结果：糖尿病性黄斑水肿患者的平均±SD视力（相当于Snellen的LogMAR）从治疗前的0.84±0.58LogMAR显着提高到治疗后6周的0.69±0.58LogMAR（平均差异：0.15±0.32LogMAR；95％CI：0.04至0.25；p=0.01）。另一方面，平均黄斑厚度±SD，从治疗前的316.54±75.35μm显着降低（p<0.001）至治疗后的275.54±57.43μm。虽然年龄和治疗前视力较差可以预测治疗后视力的改善，治疗前较高的黄斑中心厚度预示着玻璃体内注射贝伐单抗后黄斑中心厚度的改善.
结论：在患有糖尿病性黄斑水肿的非洲患者中，玻璃体内注射贝伐单抗治疗可产生短期视力改善和中央黄斑厚度减少。
方法：进行了一项回顾性横断面研究，以评估2014年1月至2019年7月在加纳接受玻璃体内贝伐单抗注射（1.25mg/0.05ml）治疗糖尿病性黄斑水肿的39例患者（平均年龄±SD：61.4±15.0岁）的39只眼。收集治疗前和治疗后6周的视力和黄斑中心厚度的数据，并使用配对t检验进行分析。还进行了普通最小二乘线性回归分析，以确定视力改善与治疗后黄斑中心厚度和其他预测变量之间的关系。
结果：糖尿病性黄斑水肿患者的平均±SD视力（相当于Snellen的LogMAR）从治疗前的0.84±0.58LogMAR显着提高到治疗后6周的0.69±0.58LogMAR（平均差异：0.15±0.32LogMAR；95％CI：0.04至0.25；p=0.01）。另一方面，平均黄斑厚度±SD，从治疗前的316.54±75.35μm显着降低（p<0.001）至治疗后的275.54±57.43μm。虽然年龄和治疗前视力较差可以预测治疗后视力的改善，治疗前较高的黄斑中心厚度预示着玻璃体内注射贝伐单抗后黄斑中心厚度的改善.
结论：在患有糖尿病性黄斑水肿的非洲患者中，玻璃体内注射贝伐单抗治疗可产生短期视力改善和中央黄斑厚度减少。
